This protocol describes the recovery of infectious Zika virus from a two-plasmid infectious cDNA clone.
Infectious cDNA clones allow for genetic manipulation of a virus, thus facilitating work on vaccines, pathogenesis, replication, transmission and viral evolution. Here we describe the construction of an infectious clone for Zika virus (ZIKV), which is currently causing an explosive outbreak in the Americas. To prevent toxicity to bacteria that is commonly observed with flavivirus-derived plasmids, we generated a two-plasmid system which separates the genome at the NS1 gene and is more stable than full-length constructs that could not be successfully recovered without mutations. After digestion and ligation to join the two fragments, full-length viral RNA can be generated by in vitro transcription with T7 RNA polymerase. Following electroporation of transcribed RNA into cells, virus was recovered that exhibited similar in vitro growth kinetics and in vivo virulence and infection phenotypes in mice and mosquitoes, respectively.
Zika virus (ZIKV; Family Flaviviridae: Genus Flavivirus) is a mosquito-borne flavivirus that arrived in Brazil in 2013-14 and was subsequently associated with a massive outbreak of febrile illness that spread throughout the Americas1. In addition, ZIKV has been linked with severe disease outcomes, such as Guillain-Barré syndrome in adults and microcephaly in fetuses and neonates2. Little was known about ZIKV before its rapid spread in the western hemisphere. This included a lack of molecular tools, thus hindering mechanistic research. Molecular tools for viruses, such as infectious cDNA clones, facilitate vaccine and antiviral therapeutic development, and allow for the assessment of viral genetic factors related to differential viral pathogenesis, immune response and viral evolution.
Flavivirus infectious clones are known to be highly unstable in bacteria due to cryptic prokaryotic promoters present in their genomes3. Several approaches have been used to ameliorate this problem; including insertion of tandem repeats upstream of viral sequences4, mutation of putative prokaryotic promoter sequences5, splitting the genome into multiple plasmids6, low-copy number vectors (including bacterial artificial chromosomes)7,8 and insertion of introns in the viral genome9. One full-length system without modifications has been described for ZIKV; however, this clone appeared to be attenuated in cell culture and in mice10. Other groups have engineered introns into the ZIKV genome, allowing for disruption of unstable sequences in bacteria that can be spliced out in mammalian cells in vitro for the production of infectious virus11,12. Additionally, a PCR-based system entitled Infectious-Subgenomic-Amplicons has been used successfully to rescue the prototype MR766 strain of ZIKV13. The approach described here requires no foreign sequences, but rather disrupts the genome at the region of high instability by using multiple plasmids, which has previously been used successfully with yellow fever6, dengue14,15 and West Nile viruses16. Furthermore, the addition of the hepatitis D ribozyme sequence at the viral genomic termini facilitates the creation of an authentic 3' end without the need for the addition of a linearization site. Additionally, both plasmids are constructed in a low-copy number vector (pACYC177, ~15 copies per cell) to mitigate any residual toxicity17. The virus recovered displays a growth profile comparable to parental virus in in vitro growth curves in 8 cell lines comprising a variety of cell-types derived from both mammals and insects, and has exhibited identical pathogenic profiles in mice and infection, dissemination and transmission rates in mosquitoes18.
Herein, we detail a protocol describing how to grow the infectious clone plasmids, generate full-length viral RNA (the viral genome) in vitro, and recover infectious virus in cell culture. First, we describe the propagation of plasmids in bacteria or bacteria-free amplification using rolling circle amplification (RCA). Next, we show how the two plasmids are digested and then subsequently ligated together to generate full-length virus. Finally, we describe the production of transcribed RNA and its subsequent electroporation into Vero cells, followed by titration of recovered virus (Figure 1). The approach described is rapid, allowing for recovery of infectious virus stocks in 1-2 weeks.
1. Transform and Recovery of Infectious Clone Plasmids
2. Preparation of Sufficient Plasmid DNA for Ligation
NOTE: Ligation and subsequent electroporation requires a sufficient amount of plasmid DNA that must be generated via either maxiprep or RCA. While maxiprep is the traditionally used approach, RCA offers the advantage of not requiring bacteria, thus removing the potential for plasmid-induced toxicity in bacteria that can result in instability events.
Primer Name | Sequence (5' – 3') |
ZIKV PRVABC59 1For. | AGTTGTTGATCTGTGTGAATCAGAC |
ZIKV Conserved 632For. | GCCCTATGCTGGATGAGG |
ZIKV Conserved 692Rev. | GGTTCCGTACACAACCCAAGTTG |
ZIKV Conserved 1313Rev. | CTCCCTTTGCCAAAAAGTCCACA |
ZIKV Conserved 1201For. | CCAACACAAGGTGAAGCCTAC |
ZIKV Conserved 1663For. | GCAGACACCGGAACTCCACACT |
ZIKV Conserved 2008For. | CAGATGGCGGTGGACATGC |
ZIKV Conserved 2350Rev. | GTGAGAACCAGGACATTCCTCC |
ZIKV Conserved 2605For. | TACAAGTACCATCCTGACTCCC |
ZIKV Conserved 3499Rev. | GCCTTATCTCCATTCCATACCA |
ZIKV Conserved 3961Rev. | TTGCCAACCAGGCCAAAG |
ZIKV Conserved 4132For. | CATTTGTCATGGCCCTGG |
ZIKV Conserved 4561Rev. | CTATTGGGTTCATGCCACAGAT |
ZIKV Conserved 4665For. | GACCACAGATGGAGTGTACAGAGT |
ZIKV Conserved 5189Rev. | AAGACAGTTAGCTGCTTCTTCTTCAG |
ZIKV Conserved 5219For. | GAGAGTTCTTCCTGAAATAGTCCGTGA |
ZIKV Conserved 6086Rev. | CTTGCTTCAAGCCAGTGTGC |
ZIKV Conserved 6119For. | GCCTCATAGCCTCGCTCTATCG |
ZIKV Conserved 6721Rev. | CCATTCCAAAGCCCATCTTCCC |
ZIKV Conserved 6769For. | CCAGCCAGAATTGCATGTGTCC |
ZIKV Conserved 7209Rev. | ATCATTAGCAGCGGGACTCCAA |
ZIKV Conserved 7343For. | GTTGTGGATGGAATAGTGGT |
ZIKV Conserved 8243For. | TGCCCATACACCAGCACTATGA |
ZIKV PRVABC59 8893Rev. | TGCATTGCTACGAACCTTGTTG |
ZIKV conserved 9133For. | AGCCCTTGGATTCTTGAACGAGGA |
ZIKV PRVABC59 9673Rev. | AACGCAATCATCTCCACTGACT |
ZIKV Conserved 9686For. | GATGATAGGTTTGCACATGCC |
ZIKV Conserved 10321Rev. | GTCCATGTACTTTTCTTCATCACCTAT |
ZIKV Conserved 10455For. | CAGGAGAAGCTGGGAAACC |
ZIKV Conserved 10621Rev. | CAGATTGAAGGGTGGGGAAGGTC |
Table 1: Primers for sequencing cDNA clones. Plasmids can be sequenced entirely with the primers listed. Primers marked as "conserved" indicate that they are likely able to sequence/amplify all genotypes of ZIKV. Primers labelled as "PRVABC59" are specific to this strain but may also work for other Asian genotype strains and possibly other genotypes.
3. Preparation of In Vitro Transcribed RNA
4. Rescue of Infectious Virus by Electroporation
5. Titration of Recovered Virus
The protocol described here allows for the recovery of infectious clone-derived Zika virus. Manipulating the two-plasmid infectious clone system is straightforward when performed with care, as compared to full-length versions which are highly unstable (data not shown). After digestion and ligation of the two distinct pieces, capped RNA is produced using in vitro transcription with T7 polymerase which is then electroporated into Vero cells (Figure 1). Correct plasmid sequence can be monitored using restriction digestion as a proxy following miniprep (Figure 2a) and via Sanger sequencing after large-scale DNA production with RCA or maxiprep. After confirmation of the clones by sequencing, recovery of infectious virus requires only digestion, ligation, in vitro transcription and finally electroporation. These steps can be performed in one day. Correct digestion and ligation can be monitored by agarose gel electrophoresis (Figure 2b), allowing for troubleshooting, if necessary.
As shown in Figure 3, infectious clone-derived virus replicates to similar levels as the parental isolate in vitro in several cell lines, suggesting that the recovered virus from the cDNA replicates similarly to primary isolate. Additionally, no significant differences were observed between the infectious clone-derived virus and the parental isolate in rates of survival in mice or rates of infection, dissemination and transmission in Aedes aegypti mosquitoes (Figure 4).
Figure 1: Workflow of ZIKV rescue from a two-plasmid cDNA clone. The genome of ZIKV strain PRVABC59 was cloned in two-separate pieces into a pACYC177 plasmid backbone. The two plasmids were then digested and ligated with T4 DNA ligase. Capped-infectious RNA was then produced via in vitro transcription followed by electroporation into Vero cells. (Figure adapted from reference21). Please click here to view a larger version of this figure.
Figure 2: Gel electrophoresis to monitor digestion and ligation of cDNA clone. (A) Initial restriction digestion of miniprep derived plasmids to assess genetic stability. (B) Examples of digestion and ligation products during recovery of infectious virus from the two-plasmid clone system. Please click here to view a larger version of this figure.
Figure 3: In vitro growth kinetics of clone-derived virus. Growth kinetics of wild type PRVABC59 and infectious clone derived virus on human (SH-SY5Y, Jar and NTERA2 cI.D1), mosquito (C6/36, Aag2) and non-human primate (Vero) cell lines were assessed by plaque assay. n = 3 Error bars represent standard deviation from the mean. (Figure adapted from reference21). Please click here to view a larger version of this figure.
Figure 4: In vivo characterization of clone-derived virus in mice and mosquitoes. (A) 4-week-old male and female interferon alpha, beta and gamma receptor knockout,AG129, mice were intraperitoneally inoculated with 1,000 PFU of PRVABC59 or the infectious clone-derived virus and monitored over time for survival (n=11). Aedes aegypti mosquitoes were given an infectious bloodmeal containing ZIKV and dissected 14 days later. (B) Plaque assays were used to assess mosquito bodies (infection), legs (dissemination) or salivary secretions (transmission) for infectious virus. Rates are presented as the percent of the total mosquitoes that were tested (Figure adapted from reference21). Please click here to view a larger version of this figure.
Here we describe a method for the recovery of a bipartite infectious cDNA clone system for ZIKV. Previously described clones for ZIKV suffer from either attenuation or require the addition of introns, making plasmids larger and preventing rescue in insect cells. Infectious virus can be recovered using the two-plasmid clone system in either mammalian or insect cells (data not shown). In addition, virus recovered from this system behaves similarly to wild-type virus in several cell lines, in an immunocompromised mouse model and in mosquitoes.
Due to the presence of cryptic bacterial promoters in flavivirus genomes3, full-length flavivirus clones are difficult to work with, commonly resulting in mutations, insertions, deletions or rearrangements in plasmids. We sought to alleviate these concerns by separating the ZIKV genome into two plasmids, disrupting the toxic sequences that are present in the viral NS1 gene. This resulted in a more stable system that is also amenable to incorporating changes. Using this clone system, we have introduced several point mutations in the ZIKV genome and inserted foreign sequences in the 3′ UTR (data not shown). This system also provides an ideal starting point for studying genetic determinants of pathogenesis, construction of vaccine candidates and development of reporter viruses. Additionally, the clone-derived virus has proven to be an important tool for studying virus evolution22.
The methods described here can also be applied to new two-plasmid clone systems for other ZIKV strains or other flaviviruses, with some modifications. An important consideration for creating new virus clone systems using this approach is identifying a naturally occurring restriction enzyme site in the viral genome near the envelope-NS1 gene junction. If a suitable site cannot be found, then it is possible to generate one artificially via PCRmutagenesis. Alternatively, we have successfully rescued infectious virus by using Gibson assembly, if overlapping segments can be generated via restriction digestion (data not shown). Furthermore, it is necessary to include either a restriction enzyme cleavage site or a ribozyme sequence immediately downstream of the viral genome to ensure an authentic 3’UTR.
By using a two-plasmid approach, we found that a stable and relatively straightforward cDNA clone system for ZIKV could be developed. The infectious virus recovered from the clone possessed wild-type characteristics in vitro and in vivo. Additionally, this approach can be adapted for any flavivirus, facilitating reverse genetics approaches for other relevant viruses.
The authors have nothing to disclose.
The authors would like to thank Kristen Bullard-Feibelman, Milena Veselinovic and Claudia Rückert for their assistance in characterizing the clone-derived virus. This work was supported in part by grants from the National Institute of Allergy and Infectious Diseases, NIH under grants AI114675 (BJG) and AI067380 (GDE).
NEB Stable CompetentE. coli | New England BioLabs | C3040H | |
Carbenicillin, Disodium Salt | various | ||
Zyppy Plasmid Miniprep Kit | Zymo Research | D4036 | |
ZymoPURE Plasmid Maxiprep Kit | Zymo Research | D4202 | |
SalI-HF | New England BioLabs | R3138S | 20,000 units/ml |
NheI-HF | New England BioLabs | R3131S | 20,000 units/ml |
ApaLI | New England BioLabs | R0507S | 10,000 units/ml |
EcoRI-HF | New England BioLabs | R3101S | 20,000 units/ml |
BamHI-HF | New England BioLabs | R3136S | 20,000 units/ml |
HindIII-HF | New England BioLabs | R3104S | 20,000 units/ml |
illustra TempliPhi 100 Amplification Kit | GE Healthcare Life Sciences | 25640010 | |
NucleoSpin Gel and PCR Clean-up | Macherey-Nagel | 740609.5 | |
Shrimp Alkaline Phosphatase (rSAP) | New England BioLabs | M0371S | 1,000 units/ml |
Alkaline Phosphatase, Calf Intestinal (CIP) | New England BioLabs | M0290S | 10,000 units/ml |
T4 DNA Ligase | New England BioLabs | M0202S | 400,000units/mL |
HiScribe T7 ARCA mRNA Kit | New England BioLabs | E2065S | |
Vero cells | ATCC | CCL-81 | |
ECM 630 High Throughput Electroporation System | BTX | 45-0423 | Other machines are acceptable. |
LB Broth with agar (Miller) | Sigma | L3147 | Can be homemade as well. |
Terrific Broth | Sigma | T0918 | Can be homemade as well. |
Petri Dish | Celltreat | 229693 | |
Culture Tubes | VWR International | 60818-576 | |
T75 flasks | Celltreat | 229340 | |
T182 flasks | Celltreat | 229350 | |
1x PBS | Corning | 21-040-CV | |
RPMI 1640 with L-glutamine | Corning | 10-040-CV | |
DMEM with L-glutamine and 4.5 g/L glucose | Corning | 10-017-CV | |
Fetal Bovine Serum (FBS) | Atlas Biologicals | FP-0500-A | |
Tragacanth Powder | MP Bio | MP 104792 | |
Crystal Violet | Amresco | 0528-1006 | |
Ethanol Denatured | VWR International | BDH1156-1LP | |
6 well plate | Celltreat | 229106 | |
12 well plate | Celltreat | 229111 | |
Sequencing Oligos | IDT | see table 1 | |
Qubit 3.0 | ThermoFisher | Qubit 3.0 | other methods are acceptable. |
Qubit dsDNA BR Assay Kit | ThermoFisher | Q32850 | other methods are acceptable. |
Qubit RNA HS Assay Kit | ThermoFisher | Q32852 | other methods are acceptable. |
Class II Biosafety Cabinet | Varies | N/A | This is necessary for live-virus work. |